Literature DB >> 14706651

Structural studies of oligonucleotides containing G-quadruplex motifs using AFM.

L T Costa1, M Kerkmann, G Hartmann, S Endres, P M Bisch, W M Heckl, S Thalhammer.   

Abstract

G-quadruplex DNAs are cyclic arrays of four guanine bases binding by Hoogsteen hydrogen bonds, found in the telomeric regions of chromosomes and in transcriptional regulatory regions of several important oncogenes. Here, we used high resolution atomic force microscopy (AFM) to observe a specific guanine (G) tetrad mediated complex formation of oligonucleotides containing a G-quadruplex motifs (G-ODN) combined with a palindromic sequence under physiological extracellular conditions. These oligonucleotides have been investigated in correlation to their immunostimulatory effects. We observed structural dependence on ion concentration and G-ODN concentration, where high concentration self-assembled DNA networks were formed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706651     DOI: 10.1016/j.bbrc.2003.12.041

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.

Authors:  Klaus Zwiorek; Carole Bourquin; Julia Battiany; Gerhard Winter; Stefan Endres; Gunther Hartmann; Conrad Coester
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

2.  Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects).

Authors:  Cordula Weber; Christian Müller; Anja Podszuweit; Carmen Montino; Jörg Vollmer; Alexandra Forsbach
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

3.  Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.

Authors:  Kouji Kobiyama; Taiki Aoshi; Hirotaka Narita; Etsushi Kuroda; Masayuki Hayashi; Kohhei Tetsutani; Shohei Koyama; Shinichi Mochizuki; Kazuo Sakurai; Yuko Katakai; Yasuhiro Yasutomi; Shinobu Saijo; Yoichiro Iwakura; Shizuo Akira; Cevayir Coban; Ken J Ishii
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

4.  Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus.

Authors:  Desyreé Murta Jesus; Lilian T Costa; Daniela L Gonçalves; Carlos Alberto Achete; Marcia Attias; Nissin Moussatché; Clarissa R Damaso
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

5.  Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates.

Authors:  Montserrat Puig; Andrzej Grajkowski; Malgorzata Boczkowska; Cristina Ausín; Serge L Beaucage; Daniela Verthelyi
Journal:  Nucleic Acids Res       Date:  2006-11-27       Impact factor: 16.971

6.  Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity.

Authors:  Hiroshi Yamada; Satoshi Nagase; Kazuo Takahashi; Yoshihiro Sakoda; Hiroshi Kida; Shigefumi Okamoto
Journal:  Antiviral Res       Date:  2016-02-26       Impact factor: 5.970

7.  CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.

Authors:  Seth G Thacker; Ian L McWilliams; Beatrice Bonnet; Lydia Halie; Serge Beaucage; Swaksha Rachuri; Ranadhir Dey; Robert Duncan; Farrokh Modabber; Stephen Robinson; Graeme Bilbe; Byron Arana; Daniela Verthelyi
Journal:  PLoS Negl Trop Dis       Date:  2020-02-28

8.  Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use.

Authors:  Taiki Aoshi; Yasunari Haseda; Kouji Kobiyama; Hirotaka Narita; Hideaki Sato; Hirokazu Nankai; Shinichi Mochizuki; Kazuo Sakurai; Yuko Katakai; Yasuhiro Yasutomi; Etsushi Kuroda; Cevayir Coban; Ken J Ishii
Journal:  J Immunol Res       Date:  2015-08-25       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.